3.44

2.55% -0.09

Galectin Therapeutics Inc (GALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Galectin Therapeutics Inc stock is traded at $3.44, with a volume of 388.20K. It is down -2.55% in the last 24 hours and down -35.58% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Previous Close:

$3.53

Open:

$3.5

24h Volume:

388.20K

Relative Volume:

0.61

Market Cap:

$346.92M

Revenue:

Net Income/Loss:

$-26.25M

P/E Ratio:

-8.3923

EPS:

-0.4099

Net Cash Flow:

$-20.05M

1W Performance:

-0.29%

1M Performance:

-35.58%

6M Performance:

+24.64%

1Y Performance:

-8.51%

1-Day Range:

$3.20

$3.5462

1-Week Range:

$3.02

$3.56

52-Week Range:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name

Galectin Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

678-620-3186

Address

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Employee

Twitter

@galectingalt

Next Earnings Date

2026-08-13

Latest SEC Filings

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GALT Galectin Therapeutics Inc	3.44	316.67M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Resumed	H.C. Wainwright	Buy
Aug-13-20	Reiterated	H.C. Wainwright	Buy
Feb-13-19	Initiated	B. Riley FBR	Buy
Dec-07-17	Reiterated	H.C. Wainwright	Buy
Nov-28-17	Reiterated	H.C. Wainwright	Buy
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy
Sep-21-15	Initiated	H.C. Wainwright	Buy
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy
Jul-29-14	Reiterated	MLV & Co	Buy
Apr-02-14	Reiterated	MLV & Co	Buy
Feb-10-14	Reiterated	Aegis Capital	Buy
Jan-09-14	Reiterated	Aegis Capital	Buy
Dec-03-13	Initiated	MLV & Co	Buy
Aug-19-13	Reiterated	Aegis Capital	Buy

View All

Galectin Therapeutics Inc Stock (GALT) Latest News

Aug 15, 2026

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aug 15, 2026

Aug 14, 2026

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Aug 14, 2026

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart

Aug 14, 2026

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results - tradingview.com

Aug 14, 2026

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - tradingview.com

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com

Aug 14, 2026

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative

Aug 14, 2026

GALT Q2'26 Earnings: EPS estimate is (0.09) USD - tradingview.com

Aug 14, 2026

Aug 13, 2026

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 10, 2026

Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - tradingview.com

Aug 10, 2026

Aug 07, 2026

Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelHagopian Line - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et

Aug 06, 2026

Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat

Aug 06, 2026

Aug 05, 2026

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail

Aug 05, 2026

Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India

Aug 05, 2026

Aug 04, 2026

Galectin chairman converts $105.8 million debt to equity - Investing.com

Aug 04, 2026

Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan

Aug 04, 2026

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative

Aug 04, 2026

Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan

Aug 04, 2026

Aug 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review

Aug 03, 2026

Aug 02, 2026

Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesDemand Zone - dars.gov.et

Aug 02, 2026

Jul 31, 2026

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat

Jul 31, 2026

Jul 27, 2026